The company is successfully transitioning from pandemic-dependent revenue to a diversified diagnostic portfolio, but traders should monitor the sustainability of this growth given high customer concentration and the recent auditor change. The upcoming compliance with IVDR regulations by 2027-2029 deadlines represents a significant future risk that could impact EU market access.
Price Chart
Executive Summary
Anbio Biotechnology's 20-F filing reveals strong financial growth with net income surging 170% YoY to $6.4M in 2025, driven by a strategic shift from COVID-19 products (19.6% of revenue) to diversified non-COVID offerings (80.4% of revenue). This transition, combined with improved gross margins (87.2% in 2025 vs. 71.9% in 2024), demonstrates successful business model evolution. However, the filing is overshadowed by a recent auditor change (GGF CPA replacing HTL International) and significant customer concentration (two customers account for 47% of 2025 revenue), raising sustainability concerns.
Key Facts
- Net income increased 170% YoY to $6.4 million in 2025
- Revenue from non-COVID-19 products rose to 80.4% of total revenue in 2025, up from 46% in 2024
- Gross profit margin improved to 87.2% in 2025 from 71.9% in 2024
- Two customers accounted for 47% of total revenue in 2025
- Company changed auditors from HTL International to GGF CPA Ltd. in February 2026
- Two suppliers accounted for 100% of total purchases in 2025
Financial Impact
Revenue of $8.65 million in 2025, net income of $6.4 million, representing a 170% increase from 2024
Risk Factors
- High customer concentration (two customers account for 47% of revenue)
- Recent auditor change may raise questions about financial reporting stability
- Heavy reliance on only two suppliers (100% of purchases)
- Future regulatory risk with IVDR compliance deadlines in 2027-2029
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 11 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001185185-26-001294 |
| Document: anbioex2-1.htm | 0001185185-26-001294 |
| Document: anbioex11-2.htm | 0001185185-26-001294 |
| Document: anbioex12-1.htm | 0001185185-26-001294 |
| Document: anbioex12-2.htm | 0001185185-26-001294 |
| Document: anbioex8-1.htm | 0001185185-26-001294 |
| Document: anbioex13-1.htm | 0001185185-26-001294 |
| Document: anbioex13-2.htm | 0001185185-26-001294 |
| Document: 0001185185-26-001294-index-headers.html | 0001185185-26-001294 |
| Document: 0001185185-26-001294-index.html | 0001185185-26-001294 |
| Document: 0001185185-26-001294.txt | 0001185185-26-001294 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 19, 2026 22w ago | 6-K | $32.34 $10.26 | ▼ −68.27% | ▼ −74.56% | $3.70 (−88.56%) |
Apr 27, 2026 25w ago | 6-K | $27.81 $9.74 | ▲ +64.98% | ▲ +68.97% | $3.70 (+86.70%) |
Apr 7, 2026 28w ago | 20-F | $26.94 $12.70 | ▼ −52.86% | ▼ −63.31% | $3.70 (−86.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers